# SHANMU

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanmu

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.shanmu.ltd
- Total disclosed funding: $15M
- Latest round: Series A (May 6, 2026)
- Investors on record: 9

## About

Founded in 2020 and based in Shenzhen, China, Shanmu (Shenzhen) Biotechnology Co., Ltd., trading as SHANMU, operates as a digital healthcare services company that focuses on the research and development of home health monitoring products. It was recognized as the National High-tech Enterprise. The team members come from UCLA, Tsinghua University, Manchester University, and other universities. Hequan Lin, the CEO of the company, graduated from the Georgia Institute of Technology and used to found Mercury Bionics. The company has applied for 53 patents. In May 2026, it raised approximated CNY 100 million in series A funding led by Stony Creek Capital, with participation from AfterShokz, Bojiang Capital Management Group, Yonghua Capital, Shanghai Angel Group, Zhixing Research Institute, Wanwuwei Venture Capital and others.
The company's main product is a real-time urinalysis health management robot, SHANMU S1, combining multi-spectrum sensing chips and AI algorithms, which can read and analyze more than 10 types of urine metabolism indexes, covering kidney function, endocrine, acid-base balance, etc. The data can be viewed through the SHANMU APP, which explains abnormal indicators and medical advice. Its perception series products have completed controlled clinical trials in several hospitals.
The company mainly generates revenue from the sale of miniature home AI health management products and related services.
SHANMU will use the series A funding in May 2026 to advance the launch of its DTC consumer healthcare products, promote the delivery and implementation of B2B customized modules, and carry out the application for domestic and international medical registration certificates.

## Funding rounds

- Series A, May 6, 2026, $15M — Yonghua Capital, Bojiang Capital Management Group, Wanwuwei Venture Capital, Stony Creek Capital, Zhixing Research Institute, Shanghai Angel Group, AfterShokz
- Angel, Aug 21, 2023 — QF Capital, Hofan Venture Capital

## Investors

- QF Capital (https://capitalatlas.ai/funds/qf-capital) — Angel
- Hofan Venture Capital (https://capitalatlas.ai/funds/hofan-venture-capital) — Angel
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Bojiang Capital Management Group (https://capitalatlas.ai/funds/bojiang-capital-management-group) — Series A
- Wanwuwei Venture Capital — Series A
- Stony Creek Capital (https://capitalatlas.ai/funds/stony-creek-capital) — Series A
- Zhixing Research Institute — Series A
- Shanghai Angel Group — Series A
- AfterShokz — Series A